COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,804 Articles (22,527 medRxiv, 8,277 bioRxiv)

Most recent first Previous |  Page 930: Articles 9291-9300  | Next

Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons
Chaguza, C., Coppi, A., Earnest, R., Ferguson, D., Kerantzas, N., Warner, F., Young, H. P., Breban, M. I., Billig, K., Koch, R. T., Pham, K., Kalinich, C. C., Ott, I. M., Fauver, J. R., Hahn, A. M., Tikhonova, I. R., Castaldi, C., Kumar, B. D., Pettker, C. M., Warren, J. L., Weinberger, D. M., Landry, M. L., Peaper, D. R., Schulz, W., Vogels, C. B. F., Grubaugh, N. D.
10.1101/2022.01.22.22269660 — Posted: 2022-01-25 Discussion: Onsite
Binding of Human ACE2 and RBD of Omicron Enhanced by Unique Interaction Patterns Among SARS-CoV-2 Variants of Concern
Kim, S., Liu, Y., Ziarnik, M., Cao, Y., Zhang, X. F., Im, W.
10.1101/2022.01.24.477633 — Posted: 2022-01-25
Structural Ramifications of Spike Protein D614G Mutation in SARS-CoV-2
Dokainish, H. M., Sugita, Y.
10.1101/2022.01.24.477651 — Posted: 2022-01-25
The Existence of At Least Three Genomic Signature Patterns and At Least Seven Subtypes of COVID-19 and the End of the Disease
Zhang, Z.
10.1101/2022.01.24.477579 — Posted: 2022-01-25
Converting non-neutralizing SARS-CoV-2 antibodies targeting conserved epitopes into broad-spectrum inhibitors through receptor blockade
Weidenbacher, P. A.-B., Waltari, E., de los Rios Kobara, I., Bell, B. N., Pak, J. E., Kim, P. S.
10.1101/2022.01.24.477625 — Posted: 2022-01-25
Emergence of glycogen synthase kinase-3 interaction domain enhances phosphorylation of SARS-CoV-2 nucleocapsid protein
Yun, J. S., Kim, N. H., Song, H., Cha, S. Y., Hwang, K. H., Lee, J. E., Jeong, C.-H., Song, S. H., Kim, S., Cho, E. S., Kim, H. S., Yook, J. I.
10.1101/2022.01.24.477037 — Posted: 2022-01-25
The effect of COVID-19 mRNA vaccine on respiratory system: human lung carcinoma cells by means of Raman spectroscopy and imaging.
Abramczyk, H., Surmacki, J. M.
10.1101/2022.01.24.477476 — Posted: 2022-01-25
Template-based design of peptides to inhibit SARS-CoV-2 RNA-dependent RNA polymerase complexation.
Chenna, A., Khan, W. H., Dash, R., Rathore, A. S., Goel, G.
10.1101/2022.01.24.477502 — Posted: 2022-01-25
Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail
Addetia, A., Park, Y.-J., Starr, T., Greaney, A. J., Sprouse, K., Bowen, J. E., Tiles, S. W., Van Voorhis, W. C., Bloom, J. D., Corti, D., Walls, A. C., Veesler, D.
10.1101/2022.01.21.477288 — Posted: 2022-01-25
Substantial immune response in Omicron infected breakthrough and unvaccinated individuals against SARS-CoV-2 variants of concerns
Yadav, P. D., Sapkal, G., Sahay, R. R., Potdar, V., Deshpande, G., Patil, D. Y., Nyayanit, D. A., Shete, A. M., Shastri, J., Awate, P., Malhotra, B., Abraham, P.
10.1101/2022.01.24.477043 — Posted: 2022-01-25

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).